

NEUROVASCULAR DYSFUNCTION BIOCHIP

EARLY DIAGNOSIS CAN MAKE A DIFFERENCE



Powered by Biochip Array Technology

Biochip enables rapid and precise multianalyte detection from a single patient sample, utilising a biomarker algorithm to offer a highly sensitive screen to stratify neurovascular dysfunction.



Biochip enables clinicians to accurately identify stroke, classify stroke subtypes, triage, and intervene immediately.



Biochip monitors patient response to treatment in realtime, enabling faster tailored clinical intervention.




Biochip improves patient outcomes through rapid targeted treatment plans



Biochip could save UK hospitals over £500 million/ year through shorter ICU stays, efficient resource use, and fewer complications and readmissions.

Data-Driven Risk Stratification

The Neurovascular Dysfunction Biochip provides clinicians with rapid quantitative results of 8 key biomarkers, facilitating fast and accurate classification of neurovascular dysfunction in an ICU setting.



Biomarkers

Glutathione S-transferase Pi (GSTPi)	Glial Fibrillary Acidic Protein (GFAP)	Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1)
Parkinson Disease Protein 7 (PARK7)	Fatty Acid Binding Protein 3 (FABP3)	D-Dimer
Nucleoside Diphosphate Kinase A (NDKA)	Interleukin-6 (IL-6)	-

Product Information



Sample Type Plasma



Samples Per Cartridge 2



 $\begin{array}{c} \text{Sample Volume} \\ 400 \mu I \end{array}$



Result Type Quantitative



Time to Result 39 Minutes